Serum Signatures: Volatile Organic Profiling for Early Hepatocellular Carcinoma Detection

The Molecular Urgency of Early Hepatocellular Carcinoma Detection

Hepatocellular carcinoma (HCC) remains one of the most lethal malignancies due to its asymptomatic progression and limited therapeutic windows. Its pathogenesis is tightly interwoven with chronic hepatic inflammation, viral hepatotropism, and metabolic dysregulation that culminate in cirrhosis and hepatocellular transformation. Traditional detection methods, such as ultrasonography and serum alpha-fetoprotein (AFP) testing, often fail to capture the molecular onset of disease because of low specificity and high rates of false positives. The molecular heterogeneity of HCC renders singular biomarkers inadequate, compelling research toward composite metabolic signatures that better reflect biochemical states of malignancy. Volatile organic compounds (VOCs), as secondary metabolites of altered cellular metabolism, have emerged as a class of system-level indicators capable of representing tumor-derived biochemical flux. Understanding their serum expression profiles offers not only a metabolic fingerprint of tumor physiology but also a practical avenue for early, non-invasive detection.

Early-stage hepatocarcinogenesis disrupts redox homeostasis and lipid peroxidation pathways, producing reactive aldehydes, ketones, and alcohols that volatilize into detectable serum biomarkers. These metabolites are downstream reflections of enzymatic dysregulation in fatty acid oxidation and cytochrome P450 metabolism, processes often distorted by oncogenic mutations and chronic hepatic insult. The volatile metabolites thereby encode a map of hepatic oxidative stress and microenvironmental shifts within serum chemistry. Gas chromatography–ion mobility spectrometry (GC-IMS) introduces a sensitive analytical frontier that captures these low-abundance volatiles without extensive sample pretreatment. Unlike conventional mass spectrometric methods requiring elaborate preparation and vacuum systems, GC-IMS maintains analytical integrity through ambient ionization and nitrogen drift, simplifying the path from sample to readout. The result is a high-resolution metabolic profile capable of discriminating between malignant and non-malignant hepatic states.

Clinicians have long struggled with balancing diagnostic precision and population-scale feasibility in HCC screening. Imaging modalities, although effective for localized assessment, cannot meet the throughput demands for routine surveillance across at-risk populations. The promise of serum VOC detection lies in its ability to act as a metabolic sentinel, identifying biochemical aberrations before structural manifestations appear. As a minimally invasive method, serum VOC profiling aligns with the clinical imperative for accessible, repeatable, and cost-efficient diagnostics. Its non-reliance on radiological infrastructure allows integration into resource-limited health systems, transforming early liver cancer detection into a scalable preventive strategy. The molecular granularity achieved through GC-IMS complements traditional imaging, forming a dual diagnostic architecture that bridges metabolic and anatomical data.

The clinical translation of VOC-based diagnostics depends on rigorous chemometric modeling and standardized sample handling. While analytical sensitivity is essential, interpretive robustness ensures reproducibility across diverse patient populations and instruments. Hence, studies employing GC-IMS integrate principal component analysis (PCA) and partial least-squares discriminant analysis (PLS-DA) to distinguish disease-specific volatile profiles from background biological noise. Such computational integration shifts biomarker discovery from reductionist enumeration to multivariate pattern recognition, reinforcing the mechanistic and diagnostic validity of the detected volatiles. The following sections delve into how GC-IMS mechanistically isolates, differentiates, and validates these spectral signatures, redefining how metabolic disturbances are visualized in liver cancer diagnostics.

Gas Chromatography–Ion Mobility Spectrometry: Physics, Chemistry, and Precision

Gas chromatography–ion mobility spectrometry integrates two orthogonal analytical principles—separation by volatility and differentiation by ion mobility—to yield multidimensional chemical information. In GC, analytes are vaporized and segregated based on interaction kinetics with the stationary phase of the capillary column, enabling retention-time differentiation of structurally distinct molecules. These volatiles are then introduced into the ion mobility spectrometer, where they are ionized under a controlled electric field and drift through a neutral gas medium. Each molecule’s drift time is dictated by its mass, charge, and collisional cross-section, producing a unique mobility signature. When these variables are plotted across drift and retention coordinates, a three-dimensional spectrum emerges that effectively encodes both compositional and structural information. This integration allows the simultaneous discrimination of multiple VOCs within a single serum sample.

The GC-IMS system employed in this study utilized a tritium-based ionization source, which provides soft ionization energy that preserves molecular integrity. The drift tube was maintained under a steady electric field and at a controlled thermal regime, ensuring consistent ion propagation and minimizing peak deformation. Nitrogen gas, serving as both carrier and drift medium, enhanced ion mobility uniformity due to its low molecular weight and inertness. The resulting three-dimensional chromatograms revealed the spectral fingerprints of VOCs—where red intensities indicated elevated concentrations and blue zones denoted depletion relative to reference serum. Through this setup, even minute biochemical deviations could be visualized as distinct spectral perturbations, capturing the molecular heterogeneity that defines HCC.

The analytical advantage of GC-IMS lies in its capacity to resolve and quantify semi-volatile and thermally labile compounds that would otherwise degrade in high-temperature GC-MS systems. Its real-time detection capability facilitates comparative analysis across multiple biological replicates without the need for sample derivatization. This approach also aligns with sustainability and cost-efficiency standards, requiring no consumable reagents beyond carrier gas and vials. Importantly, the platform’s adaptability allows for potential miniaturization into portable devices—a critical step toward bedside or field-based diagnostics. As an ion-mobility-based instrument, GC-IMS functions at the intersection of analytical chemistry and bioinformatics, translating electrophysical behavior into clinically interpretable data.

The fidelity of GC-IMS detection depends on advanced computational deconvolution, transforming raw ion-mobility data into structured biochemical patterns. Each dataset is processed into a multidimensional matrix through VOCal and OmicShare software pipelines, followed by pattern recognition algorithms that identify statistically discriminant features. By integrating PCA and PLS-DA modeling, researchers can distinguish the dominant variance components correlating with HCC pathology. This mathematical parsing does not merely visualize data—it decodes biochemical hierarchies that reflect metabolic pathway disruption. The forthcoming sections explore how these computational frameworks validated the distinct serum VOC fingerprints that separate HCC patients from non-cancer controls.

Chemometric Discrimination of Hepatocellular VOC Profiles

Chemometrics serves as the computational backbone of modern VOC biomarker discovery, transforming the complex multidimensional outputs of GC-IMS into clinically meaningful classifications. Principal component analysis (PCA) was employed to extract the most informative variance across serum samples, delineating clusters representative of malignant versus non-malignant metabolic states. The PCA model demonstrated distinct group separation, signifying that HCC patients exhibited a consistent divergence in serum VOC composition compared to healthy controls. These separations were not artifacts of sampling but reflections of biochemical remodeling induced by hepatocarcinogenesis. The relative proximity among individual HCC samples underscored the shared metabolic perturbations characteristic of the disease, whereas the tight grouping of controls affirmed the stability of physiological VOC baselines.

Partial least-squares discriminant analysis (PLS-DA) refined this separation by assigning discriminatory weight to each detected compound, thereby quantifying their contribution to class distinction. Compounds such as n-octanal, 1-pentanol, 2-hexenal, and (E)-2-octenal displayed variable importance projection (VIP) scores exceeding unity, highlighting their dominant influence in differentiating disease states. These aldehydes and alcohols are biochemical byproducts of lipid peroxidation, whose suppression in HCC patients indicates compromised oxidative metabolism and reduced fatty acid degradation. Conversely, elevated tetrahydrofuran, benzaldehyde, and 1-butanol levels in specific HCC outliers reflect secondary metabolic adaptation, possibly linked to altered microsomal enzyme activity. Such multivariate analyses convert spectrometric data into a metabolic taxonomy of cancer-associated volatility, mapping the molecular trajectory from normal hepatocyte function to malignancy.

The reliability of chemometric modeling hinges on cross-validation against permutation tests that evaluate the overfitting risk inherent in small-sample datasets. The robustness of the PLS-DA model was reinforced by high predictive alignment and substantial inter-class distance between malignant and non-malignant clusters. This computational precision ensures that the discriminative signatures are genuine reflections of metabolic biology rather than stochastic variation. The integration of chemometric analytics into diagnostic workflows thereby advances serum VOC analysis from exploratory chemistry to quantitative medicine. The statistical rigor also facilitates longitudinal application, enabling the monitoring of therapeutic response through evolving VOC signatures over time.

Chemometrics extends beyond diagnosis—it forms a bridge to mechanistic insight. The depletion of unsaturated aldehydes such as 2-hexenal in HCC reflects diminished lipid β-oxidation, while accumulation of furans suggests compensatory shunting through alternative redox pathways. These molecular redistributions reveal how hepatocellular carcinoma reconfigures energy metabolism to sustain proliferative advantage. In future translational applications, coupling chemometric outputs with enzymatic pathway databases could allow reverse-inference of dysregulated biochemical nodes. Thus, VOC-based modeling not only identifies disease but also narrates its metabolic etiology, offering a quantitative scaffold for systems-level oncology.

Metabolic Mechanisms Underlying Volatile Organic Differentiation

The volatile metabolic landscape of HCC arises from a network of oxidative stress, mitochondrial dysfunction, and peroxidative membrane breakdown. Aldehydes such as n-nonanal and heptanal are products of omega-oxidation of fatty acids, a process often suppressed when cytochrome P450 isoforms become downregulated in cirrhotic hepatocytes. Alcohols, including 1-pentanol and 1-octen-3-ol, emerge from secondary reduction of reactive aldehydes, reflecting compensatory detoxification attempts via alcohol dehydrogenase pathways. The depletion of these metabolites in HCC serum indicates a global impairment in hepatic redox cycling and an accumulation of unreduced peroxides. Such metabolic collapse reshapes the volatile fingerprint toward chemical simplicity—an absence of oxidative intermediates betraying mitochondrial exhaustion. VOC analysis therefore reconstructs the biochemical pathology of HCC with molecular granularity unavailable to imaging or proteomics alone.

Meanwhile, compounds such as benzaldehyde and tetrahydrofuran signify alternative metabolic shifts under carcinogenic stress. Benzaldehyde can originate from the degradation of aromatic amino acids such as phenylalanine, while tetrahydrofuran suggests polymeric oxidative rearrangements of lipids and carbohydrates. Their relative enrichment in certain HCC subtypes highlights tumor heterogeneity in metabolic adaptation. The altered ratios between aldehydes and ketones capture this metabolic diversity, revealing that not all malignant hepatocytes follow a uniform biochemical trajectory. These molecular disparities could, in future applications, delineate molecular subtypes of HCC with prognostic or therapeutic relevance. Each volatile signature thereby represents a dynamic equilibrium between oxidative injury, enzymatic compensation, and cellular survival strategy.

The advantage of VOC profiling lies in its ability to integrate systemic and localized biochemical perturbations. Unlike tissue biopsies confined to spatially restricted lesions, serum VOCs encode molecular echoes of distributed pathophysiological processes. The observed depletion of lipid-derived volatiles parallels the downregulation of β-oxidation enzymes seen in transcriptomic studies, validating VOCs as proxies for underlying gene expression shifts. By aligning metabolic chemistry with genomic architecture, GC-IMS transforms VOCs from abstract signals into interpretable biomarkers reflecting cellular bioenergetics. Such molecular convergence strengthens the credibility of VOC detection as an adjunct diagnostic modality for liver cancers and potentially other metabolic malignancies.

Importantly, this biochemical understanding provides a framework for developing predictive models beyond descriptive profiling. The volatility kinetics of aldehydes and alcohols can be parameterized into dynamic equations that forecast progression or remission trends in HCC patients. With machine-learning-assisted interpretation, future GC-IMS instruments could autonomously classify disease states in real time, refining precision oncology into metabolic surveillance. These implications extend beyond cancer diagnostics, suggesting the emergence of a new discipline—serum volatilomics—where chemical thermodynamics meet clinical decision-making.

Toward Clinical Integration and Future Diagnostic Infrastructures

The translation of GC-IMS–based serum volatilomics from laboratory to clinic requires optimization across analytical, computational, and ethical dimensions. First, sample standardization must be codified to minimize preanalytical variation arising from diet, medication, or circadian influences on metabolite flux. The portability and affordability of GC-IMS platforms position them uniquely for deployment in low-resource settings, but calibration across instruments remains a technical challenge. Developing certified reference materials for serum VOCs will enable interlaboratory harmonization and strengthen clinical credibility. Furthermore, coupling GC-IMS output with cloud-based chemometric databases could allow decentralized diagnostic networks where metabolic patterns are cross-referenced in real time. Such infrastructure would democratize cancer screening by making high-resolution biochemical detection globally accessible.

Clinically, integrating VOC detection as a secondary diagnostic layer enhances surveillance accuracy without replacing established imaging and serologic tools. A patient flagged by abnormal VOC spectra could be prioritized for imaging confirmation, improving triage efficiency. This complementary model leverages the sensitivity of VOC analytics with the specificity of imaging, achieving diagnostic synergy. In population health management, such dual-layer systems could identify asymptomatic cases earlier, facilitating curative interventions such as resection or transplantation before metastasis. The economic implications are profound—early detection reduces treatment costs while extending survival outcomes, aligning with public health objectives.

Beyond hepatocellular carcinoma, the VOC paradigm offers a blueprint for metabolomic diagnostics in other systemic diseases. Similar volatile shifts have been observed in lung, gastric, and pancreatic malignancies, suggesting shared oxidative and enzymatic disturbances. Thus, the serum volatilome may represent a universal chemical mirror of pathophysiological stress. Continued refinement of GC-IMS technologies, particularly through machine-learning-driven spectral deconvolution, could generalize this diagnostic model across multiple clinical domains. The convergence of analytical chemistry, bioinformatics, and oncology thus signals an inflection point in precision diagnostics, where invisible molecules narrate the earliest biochemical whispers of disease.

As this field advances, ethical and translational considerations must parallel technical innovation. The handling of volatile metabolic data intersects with privacy, consent, and the potential commodification of biochemical information. Establishing regulatory frameworks to govern volatilomic diagnostics will be as critical as refining the hardware itself. Ultimately, the clinical vision of GC-IMS is not merely technological—it is philosophical, redefining how we perceive disease detection: from the invasive to the invisible, from the anatomical to the molecular, and from the reactive to the anticipatory.

Study DOI: https://doi.org/10.3389/fchem.2025.1672220

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CpE

Editor-in-Chief, PharmaFEATURES